fertility procedure In vitro fertilization
Conditions
Interventions
The investigational treatment consists of continuous intravenous remifentanil
administration of 0.05 microram/kg/minute with the possibility of
self-administration of a remifentanil bolus with a dos
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Female subjects who undergo elective IVF/ICSI - Age 18-45 years - Informed consent
Exclusion criteria
Exclusion criteria: - Not willing to receive analgesia - Allergy for remifentanil or pethidine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The major endpoint of our trail is a reduction in pain levels as measured by a 10-point VAS during oocyte retrieval through transvaginal puncture. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoint of our trial will be: (if applicable) -difference between patient with or without endometriosis, -difference in puncture pain between left- or right ovary, -pain scores in the first three days post-puncture, -factors on influence on puncture pain, -level of sedation, -level of nausea during analgesia, -use of post-puncture medication, -IVF-related success parameters, -treatment costs, -patients* satisfaction with the analgesic method. Other study parameters: (if applicable) -Patients* demographics | — |
Countries
Netherlands
Outcome results
None listed